Moreover, combination studies with AGIs on top of treatment with a DPP-4 inhibitor in type 2 diabetic patients, showed further increase of the area under the curve (AUC) of plasma GLP-1 concentrations after a meal, compared to therapy with the DPP-4 inhibitor alone [32,41]. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.